🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524652-63-00
Ongoing Phase I

A study of enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer

2025-524652-63-00 · tracked via the Priya Life Science EU tracker
Sponsor
Sumitomo Pharma America Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
04/08/2026
Enrollment target
43
Sites
Spain, Bulgaria, Poland, Romania

Condition studied

Advanced Cancer

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524652-63-00 on CTIS ↗ ← All trials in the EU